Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocugen, Inc. - Common Stock
(NQ:
OCGN
)
1.200
-0.040 (-3.23%)
Streaming Delayed Price
Updated: 10:01 AM EST, Dec 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ocugen, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Ocugen (OCGN) Q3 2025 Earnings Call Transcript
↗
November 05, 2025
Ocugen (OCGN) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress
↗
November 05, 2025
Ocugen reports Q3 2025 results with a major revenue beat and updates on its late-stage gene therapy pipeline for blindness diseases.
Via
Chartmill
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Forecasting The Future: 4 Analyst Projections For Ocugen
↗
September 19, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 17, 2025
Via
Benzinga
Why Ocugen Stock Zoomed 12% Higher Today
↗
September 15, 2025
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.
Via
The Motley Fool
Demystifying Ocugen: Insights From 5 Analyst Reviews
↗
August 04, 2025
Via
Benzinga
A Peek at Ocugen's Future Earnings
↗
July 31, 2025
Via
Benzinga
Ocugen Shares Are Trading Higher Monday: What's Going On?
↗
September 15, 2025
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.
Via
Benzinga
Ocugen (OCGN) Q2 Revenue Jumps 20%
↗
August 01, 2025
Via
The Motley Fool
Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows
↗
August 01, 2025
Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism.
Via
Chartmill
5 Biotech Stocks with Highly Anticipated Pending Results
↗
June 26, 2025
Via
Stocktwits
Topics
Intellectual Property
Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?
↗
June 23, 2025
Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.
Via
Benzinga
A Look at Ocugen's Upcoming Earnings Report
↗
May 08, 2025
Via
Benzinga
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock
↗
March 06, 2025
Via
Benzinga
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts
↗
February 13, 2025
Via
Benzinga
Earnings Scheduled For August 1, 2025
↗
August 01, 2025
Via
Benzinga
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial
↗
June 16, 2025
Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options.
Via
Benzinga
Navigating 4 Analyst Ratings For Ocugen
↗
November 11, 2024
Via
Benzinga
A Preview Of Ocugen's Earnings
↗
November 07, 2024
Via
Benzinga
Peering Into Ocugen's Recent Short Interest
↗
August 09, 2024
Via
Benzinga
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
↗
May 12, 2025
Via
Benzinga
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts
↗
May 12, 2025
Via
Benzinga
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish
↗
May 09, 2025
CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three...
Via
Stocktwits
Topics
Lawsuit
Earnings Scheduled For May 9, 2025
↗
May 09, 2025
Via
Benzinga
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates
↗
March 05, 2025
Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.
Via
Stocktwits
Ocugen (OCGN) Q4 2024 Earnings Call Transcript
↗
March 05, 2025
OCGN earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For March 5, 2025
↗
March 05, 2025
Via
Benzinga
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
↗
November 08, 2024
OCGN earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
↗
August 08, 2024
OCGN earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
